CompoAtlas

Vitalité et concentration

Food supplement declared in France, decision dated 24 February 2025

Vitalité et concentration (PhytoSyn) is a food supplement declared in France. Status: déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité). 1 rule of use applies to its ingredients (limits and warnings).

Brand
PhytoSyn
Food business operator placing the product on the market
CHARLES LOIC EI
Status
Déclaré en France, commercialisation possible : l'administration ne s'est pas opposée à la déclaration (ce n'est ni une autorisation ni une évaluation de sécurité)
Form
Compte-gouttes
Daily dose
3 ml
Directions for use
30 gouttes (soit 1,5ml) matin et midi, diluées dans un verre d’eau
Intended populations
Population générale, Hommes et femmes de 18 ans et plus, Homme, Femme
Not recommended for (according to the manufacturer)
Adolescents (moins de 18 ans), Femmes allaitantes, Enfants (moins de 12 ans), Enfants en bas âge (1 à 3 ans), Femmes enceintes, Nourrissons (moins de 1 an), Sous anticoagulants, Sous antidépresseurs, Sous traitement médicamenteux, Enfants (de moins de 6 ans), Enfants (de moins de 10 ans)
Objectives stated by the manufacturer (these are not authorised claims)
Antioxydant, Circulation sanguine et lymphatique, Concentration, Immunité, Mémoire, Sport, Système nerveux

Declaration 256831, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 23 October 2026.

Regulatory points

Declared composition

Plants

PlantPartPreparationPer day
Ginkgo biloba L.FeuilleTeinture300 mg
Eleutherococcus senticosus (Rupr. et Maxim.) MaximRacineTeinture300 mg

Other ingredients

eau, éthanol

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Has the product changed? Photograph the packaging.

Label warnings

Consultez votre médecin en cas de prise simultanée d anticoagulants. L'emploi chez les personnes sous traitement antidépresseur est déconseillé. L'emploi chez les femmes enceintes et allaitantes est déconseillé. Avis Anses/EMA (Feuille) : 1) Déconseillé en cas d’épilepsie ; 2) Déconseillé en cas d’acte interventionnel invasif programmé ; 3 ) Déconseillé aux femmes enceintes et allaitantes ; 4) Réservé aux adultes ; 5) En cas de traitements médicamenteux, demander conseil à un professionnel de santé.

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Ginkgo biloba L.
    Read the warning, when it applies and the studies cited

    GINKGO - GINKGO BILOBA

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Blumenthal et al. 2000; WHO 1999).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking diabetes, high blood pressure or seizure medications (Brinker 2010).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you are having a surgery (Gardner and McGuffin 2013).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Do not use if you are taking blood thinners or other health products that affect blood coagulation (Gardner and McGuffin 2013; Brinker 2010; Bent 2005).

    3 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 25 July 2025

  • Eleutherococcus senticosus (Rupr. et Maxim.) Maxim
    Read the warning, when it applies and the studies cited

    ELEUTHERO - ELEUTHEROCOCCUS SENTICOSUS

    Route of administration: Oral (ESCOP 2003; Bradley 1992)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Barnes et al. 2007; ESCOP 2003).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have an acute infection (Brinker 2010; Mills and Bone 2000).

    2 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Contraindications

    Do not use if you have high blood pressure (Gardner and McGuffin 2013; Brinker 2010; Barnes et al. 2007; Blumenthal et al. 2000; Mills and Bone 2000).

    5 studies cited in the text have no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 31 October 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Brand : PhytoSyn

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Enter to analyse, Shift+Enter for a new line